What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?
Pea
Federico
F
pea.federico@aoud.sanita.fvg.it.
Furlanut
Mario
M
Viale
Pierluigi
P
D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D004334:Drug Administration Schedule; D018565:Food-Drug Interactions; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole